scholarly journals Title: Association of XRCC3, XRCC4, BAX and BCL-2 Polymorphisms with the Risk of Breast Cancer

2021 ◽  
Author(s):  
Emre Ozoran ◽  
Fadime Didem Can Trabulus ◽  
Duygu Erhan ◽  
Bahadir Batar ◽  
Mehmet Guven
Keyword(s):  
Breast Cancer ◽  
Gene Polymorphisms ◽  
Single Gene ◽  
Clinical Stage ◽  
Breast Cancer Incidence ◽  
Advanced Clinical Stage ◽  
Study Results ◽  
Pcr Rflp ◽  
Xrcc3 Thr241met ◽  
The Relationship

Abstract Background Breast cancer is the most common malignancy in women. Genetic risk factors associated with breast cancer incidence have been identified. Aims The aim of this study was to determine the association of XRCC3 Thr241Met (rs861539), XRCC4 G(-1394)T (rs6869366) DNA repair and BAX G(-248)A (rs4645878), BCL2 C(-938)A (rs2279115) apoptotic gene polymorphisms with breast cancer. Materials and Methods Genetic analysis was performed using peripheral blood samples. Gene polymorphisms were detected by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. 175 patients and 158 healthy controls were enrolled in the study. Results Breast cancer risk was 5.43 times more in individuals with AA genotype of Bax G(-248)A (rs4645878) (p = 0.002). The risk of metastasis was 11 times with this genotype. It was associated with 6 times more risk of having a tumor larger than 2 cm. The risk of breast cancer was 2.77 times more in individuals carrying the Met/Met genotype of XRCC3 Thr241Met (rs861539) (p = 0.009). The risk of having advanced clinical stage (stage III + IV) with the Met/Met genotype was 4 times more increased. No relationship with breast cancer was found with XRCC4 G(-1394)T (rs6869366) and BCL2 C(− 938)A(rs2279115) gene polymorphisms. Conclusion Multi-center trials using subjects with genetic variations are needed to establish the relationship between breast cancer and single gene polymorphism.

scholarly journals The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yujing He ◽  
Qinghua Tao ◽  
Feifei Zhou ◽  
Yuexiu Si ◽  
Rongrong Fu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protective Effect ◽  
Dairy Products ◽  
Meta Analysis ◽  
Breast Cancer Incidence ◽  
Cochrane Library ◽  
Female Population ◽  
Fermented Dairy Products ◽  
Fermented Dairy ◽  
The Relationship

Abstract Background The effect of dairy products intake on breast cancer (BC) is highly controversial. This study aims to investigate the relationship between dairy intake and BC incidence. Methods A search was carried out in PubMed, EBSCO, Web of Science, and Cochrane Library databases before January 2021. The primary objective was the risk of BC and intake of dairy products were exposure variables. Results The meta-analysis comprised 36 articles with 1,019,232 participants. Total dairy products have a protective effect on female population (hazard ratio (HR) =0.95, 95% confidence interval (CI) =0.91–0.99, p = 0.019), especially for estrogen receptor-positive (ER+) (HR = 0.79, p = 0.002) and progesterone receptor-positive (PR+) BC (HR = 0.75, p = 0.027). For ER+/PR+ BC, there is a trend of protection, but it has not reached statistical significance (HR = 0.92, p = 0.075). Fermented dairy products can reduce BC risk in postmenopausal population (HR = 0.96, 95%CI = 0.93–0.99, p = 0.021), but have no protective effect on premenopausal population (HR = 0.98, 95%CI = 0.94–1.03, p = 0.52). Non-fermented dairy products have no significant effect on BC occurrence (p > 0.05). High-fat dairy products are harmful to women, without statistical difference (HR = 1.06, 95%CI = 1.00–1.13, p = 0.066). On the contrary, low-fat dairy products can protect the premenopausal population (HR = 0.94, 95%CI = 0.89–1.00, p = 0.048). Conclusion The intake of dairy products can overall reduce BC risk in the female population, but different dairy products have varying effects on different BC subtypes and menopausal status.

Correlation between Changes in Prolactin and Melatonin Serum Levels after Radical Mastectomy

1987 ◽  
Vol 73 (3) ◽  
pp. 263-267 ◽  
Author(s):  
Paolo Lissoni ◽  
Franco Paolorossi ◽  
Sandro Barni ◽  
Gabriele Tancini ◽  
Sergio Crispino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Stage ◽  
Radical Mastectomy ◽  
Serum Levels ◽  
Axillary Node ◽  
Neoplastic Disease ◽  
Before And After ◽  
Node Involvement ◽  
Breast Cancer Growth ◽  
The Relationship

Both prolactin (PRL) and melatonin (MLT) (the most important pineal hormone) have been shown to play a role in regulating breast cancer growth. The present study was carried out to investigate the relationship between PRL and MLT secretions in human breast cancer. Twenty-four women with breast cancer, at clinical stage T1-2 N0-2 M0, were evaluated before and after radical mastectomy. As controls, 14 women who underwent surgery for reasons other than neoplastic disease were included in the study. PRL and MLT serum levels were measured by RIA before and 15 days after surgery. There were no significant differences in mean PRL serum levels between patients and controls; mean MLT serum values were significantly higher in patients than in controls. In no control subject was PRL affected by surgery. In contrast, 13/24 breast cancer women showed high PRL levels after mastectomy; the PRL rise induced by surgery was significantly higher in patients without axillary node involvement. MLT was not affected by mastectomy in 13 patients, whereas it was enhanced in 5 women and decreased in the last 6 cases. No significant correlation was seen between PRL and MLT changes induced by mastectomy. The present study shows that radical mastectomy influences PRL and MLT secretions, however, its clinical significance remains to be established.

Impact of HOTAIR Gene Polymorphism and Environmental Risk on Oral Cancer

2018 ◽  
Vol 97 (6) ◽  
pp. 717-724 ◽  
Author(s):  
S.C. Su ◽  
M.J. Hsieh ◽  
C.W. Lin ◽  
C.Y. Chuang ◽  
Y.F. Liu ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Odds Ratio ◽  
Gene Polymorphisms ◽  
Clinical Stage ◽  
Interactive Effect ◽  
Clinical Status ◽  
Betel Quid ◽  
Nucleotide Polymorphisms ◽  
Advanced Clinical Stage ◽  
Betel Quid Chewing

Genetic and acquired factors are thought to be interrelated and imperative to estimate the risk and prognosis of oral squamous cell carcinoma (OSCC). HOX transcript antisense intergenic RNA ( HOTAIR) plays crucial roles in gene regulation and is regulated in a variety of cancers. Polymorphisms in HOTAIR have been recently linked to the predisposition to diverse malignancies. In the present study, we aimed to evaluate the influences of HOTAIR gene polymorphisms, combined with environmental triggers, on the susceptibility to oral tumorigenesis. Four single-nucleotide polymorphisms of the HOTAIR gene— rs920778, rs1899663, rs4759314, and rs12427129—were tested in 1,200 control participants and 907 patients with OSCC. We detected a significant association of rs1899663 with the risk of OSCC (adjusted odds ratio, 2.227; 95% confidence interval [95% CI], 1.197 to 4.146; P = 0.012) after adjustment for 3 potential confounders: smoking, betel quid chewing, and alcohol consumption. In further analyses where habitual exposure to each of 3 environmental factors was excluded, we found that, in addition to rs1899663, non–betel quid users who carried the polymorphic allele of rs920778 were more prone to develop OSCC than were those homozygous for wild-type allele (TC: odds ratio [OR], 1.472; 95% CI, 1.069 to 2.029; P = 0.018; TC+CC: OR, 1.448; 95% CI, 1.060 to 1.977; P = 0.020). Moreover, in exploring the relationship between HOTAIR gene polymorphisms and the clinical status of only patients with OSCC who were non–betel quid chewers (excluding the advanced clinical stage), we found that rs920778 and rs4759314 were correlated with the development of large-size tumors (OR, 1.891; 95% CI, 1.027 to 3.484; P = 0.04) and increased lymph node metastasis (OR, 4.140; 95% CI, 1.785 to 9.602; P = 0.001), respectively. Further functional assessments link rs920778 to the regulation of HOTAIR expression and epigenetic status. Our results reveal an interactive effect of HOTAIR gene polymorphisms and betel quid chewing on the development and progression of oral cancer.

Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET—A French multicentric prospective study from R&D UNICANCER.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1079-1079
Author(s):  
Gerard A. Milano ◽  
Jean-Yves Pierga ◽  
Jocelyn Gal ◽  
Laurence Llorca ◽  
Coraline Dubot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Polymorphisms ◽  
Low Cost ◽  
Progression Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Pcr Rflp ◽  
Cox Analysis ◽  
Clinical Trial Information

1079 Background: Bevacizumab (Beva) is no longer unanimously recommended in the management of breast cancer (BC). Given the absence of faithful predictors of Beva treatment outcome, we made the hypothesis that constitutional gene polymorphisms could play a role in this context. We report the pharmacogenetic ancillary study of the prospective COMET trial conducted in advanced BC patients (pts) receiving first-line Beva associated with paclitaxel. Methods: Relevant targeted gene polymorphisms were analyzed (blood) in 203 prospective pts (mean age 55.3, median follow-up 24 months). VEGFA at positions -2578C > A (rs699947), -1498T > C (rs833061), -634G > C (rs2010963), and 936C > T (rs3025039) were analyzed by PCR-RFLP. VEGFR1 319A > C (rs9582036), VEGFR2 at positions 604C > T (rs2071559), 1192C > T (rs2305948), 1416T > A (rs1870377), IL8 251T > A (rs4073), CYP2C8 139C > T (rs1572080), 399T > C (rs10509681) and ABCB1 at positions 1199 C > TA (rs2229109), 2677G > TAC (rs2032582) were analyzed by Mass-Array Agena. ABCB1 1236C > T (rs1128503) and 3435T > C (rs1045642) were analyzed by pyrosequencing. All fitted HWE. Results: Median progression-free survival (PFS) was 10.8 months. VEGFR1 319A allele was associated with longer PFS (p = 0.03). The VEGFA-1498T allele was significantly associated with both longer overall survival (OS) (p = 0.005) and PFS (p = 0.065). The VEGFA -2578C allele was associated with greater OS (p = 0.002) and PFS (p = 0.071). These two VEGFA polymorphisms were in linkage disequilibrium (p < 0.0001). Multivariate Cox analysis showed that VEGFA -2578 (p = 0.001) and VEGFR2 1416 (p = 0.025) were significant predictors of OS: the score of favorable alleles (VEGFA -2575C and VEGFR2 1416T) was highly associated with OS (p = 0.0003), with median survival at 24 months being 30% for score 0 (95%CI 15-61), 65% for score 1 (95%CI 55-75) and 90% for score 2 (95%CI 67-90). Conclusions: Application of an easy-to-perform low-cost genotyping test may identify strong predictors of Beva outcome in metastatic BC pts. In the current era of precision medicine, a pharmacogenetic-based personalized Beva therapy deserves to be prospectively validated in BC pts. Clinical trial information: 2012-A00244-39.

scholarly journals Sentinel Node Biopsy After Neoadjuvant Chemotherapy In Breast Cancer: Real Life Results

2021 ◽  
Author(s):  
Marcelo Adeodato Bello ◽  
Anke Bergmann ◽  
Suzana Sales Aguiar ◽  
Marcelo Morais Barbosa ◽  
Emanuelle Narciso Alvarez Valente ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Stage ◽  
Real Life ◽  
Conservative Surgery ◽  
Lymph Node Biopsy ◽  
Multiple Model ◽  
Advanced Clinical Stage ◽  
Factors Associated ◽  
Node Biopsy

Abstract Purpose: compare demographic, clinical and treatment characteristics of women undergoing neoadjuvant chemotherapy (NAC) for breast cancer (BC) treatment according to the axillary approach and analyze factors associated with the indication of sentinel lymph node biopsy (SLNB) in a real-life scenario. Methods: retrospective cohort study in women diagnosed with BC with indication for NAC. Demographic, clinical, tumor, surgical and adjuvant treatment variables were obtained.. A univariate logistic regression was performed to evaluate the independent factors associated with SLNB indication and a multiple model was applied for adjustments. Results: A total of 918 patients were included in this study, 161 (17.5%) of whom underwent SLNB, 105 (11.4%) who underwent SLNB followed by AL and 652 (71.0%) who underwent AL only. Concerning the adjusted model, women in stage III were 95% less likely to be submitted to an SLNB (OR = 0.05 95% CI 0.01-0.17; p<0.001) compared to those in stage I. Women who underwent mastectomies exhibited a 90% lower chance of undergoing SLNB than those who underwent conservative surgery (95% CI 0.06-0.17; p <0.001). Considering NAC responses, cases with no response or presenting disease progression exhibited a 55% lower chance of undergoing SLNB compared to those displaying a total response (OR = 0.45 95% CI 0.24-0.82; p = 0.009). Conclusion: SLNB was performed in 29% of the patients following NAC. Patients presenting a more advanced clinical stage of the disease with a worse NAC response and those who underwent mastectomies were less likely to undergo SLNB.

scholarly journals SURG-12. MALIGNANT BREAST NEOPLASM AND BRAIN METASTASES: SERIES OF CASES AND MAIN APPROACHES IN A HOSPITAL COMPLEX IN BRAZIL

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii26-iii26
Author(s):  
Frederico Tavares de Lima ◽  
Nataly Regina Medeiros ◽  
Luiz Domingues Vasconcelos Filho ◽  
Bruno Leimig ◽  
Walter Matias ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Clinical Stage ◽  
Case Series ◽  
Metastatic Breast ◽  
Northeastern Brazil ◽  
Surgical Performance ◽  
Large Tumor ◽  
Advanced Clinical Stage ◽  
Surgical Interventions

Abstract Introduction With the advancement of clinical and surgical oncology, patients with breast cancer had an increase in survival. In this context, up to 30% of patients affected with metastases from this site will develop brain tumors. The latter is an important impacting factor for life quality and expectancy, therefore, it’s clinical and surgical management is essential in public health. We present some rare cases and their outcomes. Methods We describe a case series of 07 patients with breast cancer metastases to the brain, involving large portions of the dura, bone or skin. There were 64 surgical interventions of the disease in the period, but only those with more exuberant and atypical presentations were selected. The interventions were carried out in a hospital oncology complex in northeastern Brazil between 2016 and 2020.The diagnosis was based on the clinical description, laboratory and image exams, histopathology and surgical performance of the patients. Results The mean age of the patients was 49.7 years, with all patients being female. Rare presentations were observed, such as bone and skin meninges. Clinical presentations demonstrated advanced stages of the disease with a large tumor volume. Extra axial involvement was verified. All patients underwent neurosurgery for tumor removal and decompression. Biopsies were submitted to anatomopathological and immunohistochemistry examination. Corticotherapy was instituted in the immediate postoperative period and some cases had genetic analysis due to an important family history. There was a reduction in symptoms in most cases. Conclusion Although brain metastases are still a challenge for medical practice, their proper management can prolong and improve patients’ lives. Metastatic breast cancers seem to have a predilection for the central nervous system and their detection and intervention, even in an advanced clinical stage, sound as determinant for the control and severity of symptoms. Keywords Brain Neoplasms, Neoplasm Metastasis, Breast Neoplasms

scholarly journals The Relationship between Pre-miR-3131 3-bp Insertion/Deletion Polymorphism and Susceptibility and Clinicopathological Characteristics of Patients with Breast Cancer

MicroRNA ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 216-223
Author(s):  
Mahsa Azizi ◽  
Nahid Rahimi ◽  
Gholamreza Bahari ◽  
Seyed Mehdi Hashemi ◽  
Mohammad Hashemi
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Late Onset ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Increased Risk ◽  
Pcr Rflp ◽  
Risk Of Cancer ◽  
The Relationship ◽  
Control Study

Aims: This study aimed at examining the effect of 3-bp pre-miR-3131 insertion/deletion (ins/del) polymorphism on Breast Cancer (BC) risk. Objectives: Totally 403 women including 199 BC patients and 204 women who have no cancer were included in this case-control study. Genotyping of miR-3131 3-bp ins/del polymorphism was performed by mismatch PCR-RFLP method. Methods: The findings expressed that the pre-miR-3131 3-bp ins/del variant was not related to the risk of BC in all genetic tested models. While, the ins/del genotype was related to late onset BC (OR=2.53, 95%CI=1.27-4.84, p=0.008). Results: Pooled results from the meta-analysis indicated to that the pre-miR-3131 ins/del is related to with an increased risk of cancer in heterozygous (OR=1.26, 95%CI=1.06-1.51, p=0.01), dominant (OR=1.33, 95%CI=1.14-1.54, p=0.0002), and allele (OR=1.24, 95%CI=1.06-1.45, p=0.006) genetics models. Conclusion: It is concluded that, our findings did not support a relationship between pre-miR-3131 ins/del polymorphism and the risk of BC. While, this variant was significantly related to late onset BC. Combined results of this study with previous studies indicated that this polymorphism increased the risk of cancer. More studies in a study with larger population with variety of ethnicities are required to verify our findings.

scholarly journals Long noncoding RNA FGF14-AS2 inhibits breast cancer metastasis by regulating the miR-370-3p/FGF14 axis

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Yucui Jin ◽  
Ming Zhang ◽  
Rui Duan ◽  
Jiashu Yang ◽  
Ying Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Noncoding Rna ◽  
Cancer Metastasis ◽  
Clinical Stage ◽  
Breast Cancer Metastasis ◽  
Normal Breast ◽  
Advanced Clinical Stage ◽  
Cancer Tissues

Abstract Long noncoding RNAs (lncRNAs) have emerged as important regulators in cancers, including breast cancer. However, the overall biological roles and clinical significance of most lncRNAs are not fully understood. This study aimed to elucidate the potential role of a novel lncRNA FGF14-AS2 and the mechanisms underlying metastasis in breast cancer. The lncRNA FGF14-AS2 was significantly downregulated in breast cancer tissues; patients with lower FGF14-AS2 expression had advanced clinical stage. In vitro and in vivo assays of FGF14-AS2 alterations revealed a complex integrated phenotype affecting breast cancer cell migration, invasion, and tumor metastasis. Mechanistically, FGF14-AS2 functioned as a competing endogenous RNA of miR-370-3p, thereby leading to the activation of its coding counterpart, FGF14. Clinically, we observed increased miR-370-3p expression in breast cancer tissues, whereas FGF14 expression was decreased in breast cancer tissues compared to the adjacent normal breast tissues. FGF14-AS2 expression was significantly negatively correlated with miR-370-3p expression, and correlated positively to FGF14 expression. Collectively, our findings support a model in which the FGF14-AS2/miR-370-3p/FGF14 axis is a critical regulator in breast cancer metastasis, suggesting a new therapeutic direction in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document